SCHEDULE: Summer Road LLC Discloses 5.7% Stake in Ocular Therapeutix

Summer Road LLC, a Delaware family office, has reported a 5.7% beneficial ownership stake in Ocular Therapeutix, Inc., totaling 12,134,357 common shares.

Summary

• Summer Road LLC, a Delaware limited liability company operating as a family office, has filed a Schedule 13G.
• The filing reports beneficial ownership of 12,134,357 common shares of OCULAR THERAPEUTIX, INC.
• This represents 5.7% of the issuer's common stock outstanding.
• The ownership percentage is based on 213,047,472 shares outstanding as of October 31, 2025, as reported in the company's 10-Q filed on November 4, 2025.
• Summer Road LLC exercises sole voting and dispositive power over these shares through investment management agreements with three 'Family Clients'.
• Summer Road LLC has no pecuniary interest in the beneficially owned shares.
• No single Family Client individually owns more than 5% of the common stock.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities related to a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: The filing is a standard beneficial ownership disclosure, indicating a significant stake by a family office. It is generally neutral but could be seen as slightly positive as it confirms a substantial institutional holding in the company.

Positives

• A significant institutional investor, Summer Road LLC, has disclosed a 5.7% stake, potentially indicating confidence in Ocular Therapeutix, Inc.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a 5.7% stake by a family office provides transparency regarding significant ownership, which can influence investor perception and potentially liquidity.

Key Dates

Keywords

Ocular Therapeutix, Summer Road LLC, Schedule 13G, Beneficial Ownership, Common Stock, Family Office, Institutional Investor, SEC Filing, Equity Stake, 67576A100